Janumet, 1000 mg+50 mg 28 pcs

The drug Janumet is a combination of two hypoglycemic drugs with complementary (complementary) mechanism of action, designed to improve glycemic control in patients with type 2 diabetes: sitagliptin, an inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, and metformin, a representative of the biguanide class.
Sitagliptin is an orally active, highly selective DPP-4 inhibitor for the treatment of type 2 diabetes. The pharmacological effects of the class of DPP-4 inhibitor drugs are mediated by the activation of incretins.

Inhibiting DPP-4, sitagliptin increases the concentration of two known active hormones of the incretin family: glucagon-like peptide 1 (GFP-1) and glucose-dependent insulinotropic polypeptide (GIP). Incretins are part of the internal physiological system of glucose homeostasis regulation. At normal or elevated blood glucose concentrations, GFP-1 and GIP contribute to increased insulin synthesis and secretion by pancreatic beta cells. GFP-1 also inhibits glucagon secretion by pancreatic alpha cells, thus reducing glucose synthesis in the liver. This mechanism of action differs from the mechanism of action of sulfonylurea derivatives, which stimulate insulin release even at low blood glucose concentrations, which is fraught with development of sulfonyl-induced hypoglycemia not only in patients with type 2 diabetes but also in healthy individuals.

As a highly selective and effective inhibitor of DPP-4 enzyme, sitagliptin in therapeutic concentrations does not inhibit activity of related enzymes DPP-8 or DPP-9. Sitagliptin differs in chemical structure and pharmacological action from PPP-1 analogues, insulin, sulfonylurea or meglitinide derivatives, biguanides, peroxisome proliferator-activated receptor gamma agonists (PPARy), alpha-glycosidase inhibitors and amylin analogues.

Metformin is a hypoglycemic drug that increases glucose tolerance in patients with type 2 diabetes by reducing basal and postprandial blood glucose concentrations. Its pharmacological mechanisms of action are different from the mechanisms of action of oral hypoglycemic drugs of other classes. Metformin reduces glucose synthesis in the liver, reduces glucose absorption in the intestine and increases insulin sensitivity through glucose capture and utilization.

Indications

Active ingredient

Composition

One tablet contains:

Active ingredients:

Metformin hydrochloride – 1000 mg;

Sitagliptin phosphate monohydrate – 64.25 mg (equivalent to the content of 50 mg sitagliptin).

Auxiliary components:

Sodium stearyl fumarate;

Microcrystalline cellulose;

Sodium lauryl sulfate;

Povidone.

Composition of the shell:

Opadray II Red, 85 F 15464;

Polyvinyl alcohol;

Macrogol-3350;

Titanium dioxide (E171);

Red iron oxide (E172);

Black iron oxide (E172);

Talc.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Pregnancy use

Similarities